Tumor injection and immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial is testing an experimental therapy (JCXH-211) that is injected directly into the tumor, combined with an immunotherapy drug (anti-PD-1 antibody). It is for people with advanced solid tumors who have not had success with standard treatments, and it aims to help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of cancer that is a solid tumor and it has continued to grow despite standard treatment (or you could not tolerate the standard treatment).
- You are able to take care of yourself and are not bedridden (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests an investigational drug given as an injection under the skin for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses immune cells from your own tumor, grown in the lab and given back to you, potentially to help your body fight the cancer.
Hear when a new Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.